Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-01-06

AUTHORS

Nancy Perrottet, Oriol Manuel, Frédéric Lamoth, Jean-Pierre Venetz, Roland Sahli, Laurent A Decosterd, Thierry Buclin, Manuel Pascual, Pascal Meylan

ABSTRACT

BackgroundValganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining variations in the therapeutic response. This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease.MethodsSeven CMV D+/R- transplant recipients (4 kidney, 2 liver and 1 heart) were treated with valganciclovir (initial dose was 900-1800 mg/day for 3-6.5 weeks, followed by 450-900 mg/day for 2-9 weeks). DNAemia was monitored by real time quantitative PCR and ganciclovir plasma concentration was measured at trough (Ctrough) and 3 h after drug administration (C3h) by HPLC.ResultsFour patients presented with CMV syndrome, two had CMV tissue-invasive disease after prophylaxis discontinuation, and one liver recipient was treated pre-emptively for asymptomatic rising CMV viral load 5 weeks post-transplantation in the absence of prophylaxis. CMV DNAemia decreased during the first week of treatment in all recipients except in one patient (median decrease: -1.2 log copies/mL, range: -1.8 to 0) despite satisfactory ganciclovir exposure (AUC0-12 = 48 mg·h/L, range for the 7 patients: 40-118 mg·h/L). Viral clearance was obtained in five patients after a median of time of 34 days (range: 28-82 days). Two patients had recurrent CMV disease despite adequate ganciclovir exposure (65 mg·h/L, range: 44-118 mg·h/L).ConclusionsValganciclovir treatment for CMV infection/disease in D+/R- transplant recipients can thus result in variable viral clearance despite adequate ganciclovir plasma concentrations, probably correlating inversely with anti-CMV immune responses after primary infection. More... »

PAGES

2

References to SciGraph publications

  • 2009-06. Valganciclovir in Adult Solid Organ Transplant Recipients in CLINICAL PHARMACOKINETICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/1471-2334-10-2

    DOI

    http://dx.doi.org/10.1186/1471-2334-10-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1004423190

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/20053269


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antiviral Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cytomegalovirus Infections", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "DNA, Viral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ganciclovir", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organ Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation, Homologous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Valganciclovir", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Viral Load", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perrottet", 
            "givenName": "Nancy", 
            "id": "sg:person.01157645276.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157645276.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manuel", 
            "givenName": "Oriol", 
            "id": "sg:person.01311627331.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311627331.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lamoth", 
            "givenName": "Fr\u00e9d\u00e9ric", 
            "id": "sg:person.01243514131.83", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243514131.83"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Venetz", 
            "givenName": "Jean-Pierre", 
            "id": "sg:person.0676401571.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676401571.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sahli", 
            "givenName": "Roland", 
            "id": "sg:person.0761360220.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761360220.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Decosterd", 
            "givenName": "Laurent A", 
            "id": "sg:person.01344344533.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344344533.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Buclin", 
            "givenName": "Thierry", 
            "id": "sg:person.01230116133.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116133.26"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pascual", 
            "givenName": "Manuel", 
            "id": "sg:person.01205263315.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205263315.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Meylan", 
            "givenName": "Pascal", 
            "id": "sg:person.01336350503.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336350503.09"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003088-200948060-00006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046214298", 
              "https://doi.org/10.2165/00003088-200948060-00006"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2010-01-06", 
        "datePublishedReg": "2010-01-06", 
        "description": "BackgroundValganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining variations in the therapeutic response. This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease.MethodsSeven CMV D+/R- transplant recipients (4 kidney, 2 liver and 1 heart) were treated with valganciclovir (initial dose was 900-1800 mg/day for 3-6.5 weeks, followed by 450-900 mg/day for 2-9 weeks). DNAemia was monitored by real time quantitative PCR and ganciclovir plasma concentration was measured at trough (Ctrough) and 3 h after drug administration (C3h) by HPLC.ResultsFour patients presented with CMV syndrome, two had CMV tissue-invasive disease after prophylaxis discontinuation, and one liver recipient was treated pre-emptively for asymptomatic rising CMV viral load 5 weeks post-transplantation in the absence of prophylaxis. CMV DNAemia decreased during the first week of treatment in all recipients except in one patient (median decrease: -1.2 log copies/mL, range: -1.8 to 0) despite satisfactory ganciclovir exposure (AUC0-12 = 48 mg\u00b7h/L, range for the 7 patients: 40-118 mg\u00b7h/L). Viral clearance was obtained in five patients after a median of time of 34 days (range: 28-82 days). Two patients had recurrent CMV disease despite adequate ganciclovir exposure (65 mg\u00b7h/L, range: 44-118 mg\u00b7h/L).ConclusionsValganciclovir treatment for CMV infection/disease in D+/R- transplant recipients can thus result in variable viral clearance despite adequate ganciclovir plasma concentrations, probably correlating inversely with anti-CMV immune responses after primary infection.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/1471-2334-10-2", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1024946", 
            "issn": [
              "1471-2334"
            ], 
            "name": "BMC Infectious Diseases", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "10"
          }
        ], 
        "keywords": [
          "ganciclovir plasma concentrations", 
          "CMV infection/disease", 
          "transplant recipients", 
          "infection/disease", 
          "viral clearance", 
          "ganciclovir exposure", 
          "plasma concentrations", 
          "solid organ transplant recipients", 
          "CMV tissue-invasive disease", 
          "anti-CMV immune response", 
          "CMV disease treatment", 
          "median of time", 
          "recurrent CMV disease", 
          "organ transplant recipients", 
          "prospective observational study", 
          "tissue-invasive disease", 
          "viral load response", 
          "absence of prophylaxis", 
          "ResultsFour patients", 
          "CMV syndrome", 
          "prophylaxis discontinuation", 
          "liver recipients", 
          "CMV DNAemia", 
          "CMV disease", 
          "valganciclovir treatment", 
          "cytomegalovirus disease", 
          "oral prodrug", 
          "real-time quantitative PCR", 
          "primary infection", 
          "plasma levels", 
          "therapeutic response", 
          "observational study", 
          "immune response", 
          "patients", 
          "Drug Administration", 
          "valganciclovir", 
          "time quantitative PCR", 
          "disease", 
          "first week", 
          "recipients", 
          "DNAemia", 
          "disease treatment", 
          "clearance", 
          "treatment", 
          "ganciclovir", 
          "quantitative PCR", 
          "weeks", 
          "exposure", 
          "prophylaxis", 
          "discontinuation", 
          "response", 
          "syndrome", 
          "CMV", 
          "infection", 
          "administration", 
          "median", 
          "prodrug", 
          "concentration", 
          "days", 
          "PCR", 
          "factors", 
          "levels", 
          "absence", 
          "study", 
          "HPLC", 
          "time", 
          "variability", 
          "load response", 
          "variation", 
          "trough"
        ], 
        "name": "Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients", 
        "pagination": "2", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1004423190"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/1471-2334-10-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "20053269"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/1471-2334-10-2", 
          "https://app.dimensions.ai/details/publication/pub.1004423190"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:36", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_506.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/1471-2334-10-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-10-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-10-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-10-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-10-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    250 TRIPLES      21 PREDICATES      110 URIs      101 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/1471-2334-10-2 schema:about N077ed90becfb4c4fa3a44cff98e02758
    2 N19aa1a299b944ac38180870d4022c66d
    3 N28cb7298128b495c869cbbcf35bdfe0b
    4 N398773e7b0df494186326b33c8b59ed4
    5 N63353974cf6f45e9a7a37680fdf251ac
    6 N6e9c8eaa18694beda1e0cc248ee9fc50
    7 N73936067eaaf445ea9797adfe491c752
    8 N744500b547544ed19c19c6a95cd12336
    9 N8be4292d4a3f49aa977e6bd794be0857
    10 Na4aaa58860294bc4a72aa1ff12f24cbf
    11 Nacdfeabf5bbb43d9b45701c42bfdabf7
    12 Nbb08b0630a4544f191a7b6438ac050c9
    13 Nd82e41f45930411893ebc3254ab8a4c4
    14 Ne40f31c658814fa29bc136dcf60510cb
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N7be56bd0a53d4d0f866593cb3af87bf4
    18 schema:citation sg:pub.10.2165/00003088-200948060-00006
    19 schema:datePublished 2010-01-06
    20 schema:datePublishedReg 2010-01-06
    21 schema:description BackgroundValganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining variations in the therapeutic response. This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease.MethodsSeven CMV D+/R- transplant recipients (4 kidney, 2 liver and 1 heart) were treated with valganciclovir (initial dose was 900-1800 mg/day for 3-6.5 weeks, followed by 450-900 mg/day for 2-9 weeks). DNAemia was monitored by real time quantitative PCR and ganciclovir plasma concentration was measured at trough (Ctrough) and 3 h after drug administration (C3h) by HPLC.ResultsFour patients presented with CMV syndrome, two had CMV tissue-invasive disease after prophylaxis discontinuation, and one liver recipient was treated pre-emptively for asymptomatic rising CMV viral load 5 weeks post-transplantation in the absence of prophylaxis. CMV DNAemia decreased during the first week of treatment in all recipients except in one patient (median decrease: -1.2 log copies/mL, range: -1.8 to 0) despite satisfactory ganciclovir exposure (AUC0-12 = 48 mg·h/L, range for the 7 patients: 40-118 mg·h/L). Viral clearance was obtained in five patients after a median of time of 34 days (range: 28-82 days). Two patients had recurrent CMV disease despite adequate ganciclovir exposure (65 mg·h/L, range: 44-118 mg·h/L).ConclusionsValganciclovir treatment for CMV infection/disease in D+/R- transplant recipients can thus result in variable viral clearance despite adequate ganciclovir plasma concentrations, probably correlating inversely with anti-CMV immune responses after primary infection.
    22 schema:genre article
    23 schema:isAccessibleForFree true
    24 schema:isPartOf Na94a5096402342899552734a83d9c7b4
    25 Naea294922f844ca0bcbaaeeee666e27a
    26 sg:journal.1024946
    27 schema:keywords CMV
    28 CMV DNAemia
    29 CMV disease
    30 CMV disease treatment
    31 CMV infection/disease
    32 CMV syndrome
    33 CMV tissue-invasive disease
    34 DNAemia
    35 Drug Administration
    36 HPLC
    37 PCR
    38 ResultsFour patients
    39 absence
    40 absence of prophylaxis
    41 administration
    42 anti-CMV immune response
    43 clearance
    44 concentration
    45 cytomegalovirus disease
    46 days
    47 discontinuation
    48 disease
    49 disease treatment
    50 exposure
    51 factors
    52 first week
    53 ganciclovir
    54 ganciclovir exposure
    55 ganciclovir plasma concentrations
    56 immune response
    57 infection
    58 infection/disease
    59 levels
    60 liver recipients
    61 load response
    62 median
    63 median of time
    64 observational study
    65 oral prodrug
    66 organ transplant recipients
    67 patients
    68 plasma concentrations
    69 plasma levels
    70 primary infection
    71 prodrug
    72 prophylaxis
    73 prophylaxis discontinuation
    74 prospective observational study
    75 quantitative PCR
    76 real-time quantitative PCR
    77 recipients
    78 recurrent CMV disease
    79 response
    80 solid organ transplant recipients
    81 study
    82 syndrome
    83 therapeutic response
    84 time
    85 time quantitative PCR
    86 tissue-invasive disease
    87 transplant recipients
    88 treatment
    89 trough
    90 valganciclovir
    91 valganciclovir treatment
    92 variability
    93 variation
    94 viral clearance
    95 viral load response
    96 weeks
    97 schema:name Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
    98 schema:pagination 2
    99 schema:productId N63ddf42e7c274092aa664c959e602172
    100 Nc58ccf042a6e44868fd71be399a269fa
    101 Nfea5631ec45c4acf9b4a0ddbcbd05a54
    102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004423190
    103 https://doi.org/10.1186/1471-2334-10-2
    104 schema:sdDatePublished 2022-10-01T06:36
    105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    106 schema:sdPublisher N7748dd31fa754c8da2b4abedc75594f2
    107 schema:url https://doi.org/10.1186/1471-2334-10-2
    108 sgo:license sg:explorer/license/
    109 sgo:sdDataset articles
    110 rdf:type schema:ScholarlyArticle
    111 N00e3a13fabd849e987d86bb7a35f341d rdf:first sg:person.01205263315.38
    112 rdf:rest Nc177ba114e49468bbd55013645333552
    113 N077ed90becfb4c4fa3a44cff98e02758 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Prospective Studies
    115 rdf:type schema:DefinedTerm
    116 N1380bdf0792a4fb88aff3e4f9ea2e240 rdf:first sg:person.01243514131.83
    117 rdf:rest N927a1d23117f4025a8696b12279dc69a
    118 N19aa1a299b944ac38180870d4022c66d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Transplantation, Homologous
    120 rdf:type schema:DefinedTerm
    121 N28cb7298128b495c869cbbcf35bdfe0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name DNA, Viral
    123 rdf:type schema:DefinedTerm
    124 N2dde6144905b4074bc6b9d19c8bee930 rdf:first sg:person.01230116133.26
    125 rdf:rest N00e3a13fabd849e987d86bb7a35f341d
    126 N3836e901684c45e7af6e6e384c6d7c16 rdf:first sg:person.0761360220.49
    127 rdf:rest Nea0600ce5a184bffac9402d90518044a
    128 N398773e7b0df494186326b33c8b59ed4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Middle Aged
    130 rdf:type schema:DefinedTerm
    131 N63353974cf6f45e9a7a37680fdf251ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Cytomegalovirus Infections
    133 rdf:type schema:DefinedTerm
    134 N63ddf42e7c274092aa664c959e602172 schema:name doi
    135 schema:value 10.1186/1471-2334-10-2
    136 rdf:type schema:PropertyValue
    137 N6e9c8eaa18694beda1e0cc248ee9fc50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Aged
    139 rdf:type schema:DefinedTerm
    140 N71ab5c4912604b3785c1a8c70cb84f80 rdf:first sg:person.01311627331.51
    141 rdf:rest N1380bdf0792a4fb88aff3e4f9ea2e240
    142 N73936067eaaf445ea9797adfe491c752 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Valganciclovir
    144 rdf:type schema:DefinedTerm
    145 N744500b547544ed19c19c6a95cd12336 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Humans
    147 rdf:type schema:DefinedTerm
    148 N7748dd31fa754c8da2b4abedc75594f2 schema:name Springer Nature - SN SciGraph project
    149 rdf:type schema:Organization
    150 N7be56bd0a53d4d0f866593cb3af87bf4 rdf:first sg:person.01157645276.44
    151 rdf:rest N71ab5c4912604b3785c1a8c70cb84f80
    152 N8be4292d4a3f49aa977e6bd794be0857 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Antiviral Agents
    154 rdf:type schema:DefinedTerm
    155 N927a1d23117f4025a8696b12279dc69a rdf:first sg:person.0676401571.53
    156 rdf:rest N3836e901684c45e7af6e6e384c6d7c16
    157 Na4aaa58860294bc4a72aa1ff12f24cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Male
    159 rdf:type schema:DefinedTerm
    160 Na94a5096402342899552734a83d9c7b4 schema:issueNumber 1
    161 rdf:type schema:PublicationIssue
    162 Nacdfeabf5bbb43d9b45701c42bfdabf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Ganciclovir
    164 rdf:type schema:DefinedTerm
    165 Naea294922f844ca0bcbaaeeee666e27a schema:volumeNumber 10
    166 rdf:type schema:PublicationVolume
    167 Nbb08b0630a4544f191a7b6438ac050c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Female
    169 rdf:type schema:DefinedTerm
    170 Nc177ba114e49468bbd55013645333552 rdf:first sg:person.01336350503.09
    171 rdf:rest rdf:nil
    172 Nc58ccf042a6e44868fd71be399a269fa schema:name pubmed_id
    173 schema:value 20053269
    174 rdf:type schema:PropertyValue
    175 Nd82e41f45930411893ebc3254ab8a4c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Viral Load
    177 rdf:type schema:DefinedTerm
    178 Ne40f31c658814fa29bc136dcf60510cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Organ Transplantation
    180 rdf:type schema:DefinedTerm
    181 Nea0600ce5a184bffac9402d90518044a rdf:first sg:person.01344344533.08
    182 rdf:rest N2dde6144905b4074bc6b9d19c8bee930
    183 Nfea5631ec45c4acf9b4a0ddbcbd05a54 schema:name dimensions_id
    184 schema:value pub.1004423190
    185 rdf:type schema:PropertyValue
    186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    187 schema:name Medical and Health Sciences
    188 rdf:type schema:DefinedTerm
    189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    190 schema:name Clinical Sciences
    191 rdf:type schema:DefinedTerm
    192 sg:journal.1024946 schema:issn 1471-2334
    193 schema:name BMC Infectious Diseases
    194 schema:publisher Springer Nature
    195 rdf:type schema:Periodical
    196 sg:person.01157645276.44 schema:affiliation grid-institutes:grid.8515.9
    197 schema:familyName Perrottet
    198 schema:givenName Nancy
    199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157645276.44
    200 rdf:type schema:Person
    201 sg:person.01205263315.38 schema:affiliation grid-institutes:grid.8515.9
    202 schema:familyName Pascual
    203 schema:givenName Manuel
    204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205263315.38
    205 rdf:type schema:Person
    206 sg:person.01230116133.26 schema:affiliation grid-institutes:grid.8515.9
    207 schema:familyName Buclin
    208 schema:givenName Thierry
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116133.26
    210 rdf:type schema:Person
    211 sg:person.01243514131.83 schema:affiliation grid-institutes:grid.8515.9
    212 schema:familyName Lamoth
    213 schema:givenName Frédéric
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243514131.83
    215 rdf:type schema:Person
    216 sg:person.01311627331.51 schema:affiliation grid-institutes:grid.8515.9
    217 schema:familyName Manuel
    218 schema:givenName Oriol
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311627331.51
    220 rdf:type schema:Person
    221 sg:person.01336350503.09 schema:affiliation grid-institutes:grid.8515.9
    222 schema:familyName Meylan
    223 schema:givenName Pascal
    224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336350503.09
    225 rdf:type schema:Person
    226 sg:person.01344344533.08 schema:affiliation grid-institutes:grid.8515.9
    227 schema:familyName Decosterd
    228 schema:givenName Laurent A
    229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344344533.08
    230 rdf:type schema:Person
    231 sg:person.0676401571.53 schema:affiliation grid-institutes:grid.8515.9
    232 schema:familyName Venetz
    233 schema:givenName Jean-Pierre
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676401571.53
    235 rdf:type schema:Person
    236 sg:person.0761360220.49 schema:affiliation grid-institutes:grid.8515.9
    237 schema:familyName Sahli
    238 schema:givenName Roland
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761360220.49
    240 rdf:type schema:Person
    241 sg:pub.10.2165/00003088-200948060-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046214298
    242 https://doi.org/10.2165/00003088-200948060-00006
    243 rdf:type schema:CreativeWork
    244 grid-institutes:grid.8515.9 schema:alternateName Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland
    245 Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland
    246 Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland
    247 schema:name Division of Clinical Pharmacology and Toxicology, University Hospital (CHUV), Lausanne, Switzerland
    248 Microbiology Institute, University Hospital (CHUV), Lausanne, Switzerland
    249 Organ Transplantation Centre, University Hospital (CHUV), Lausanne, Switzerland
    250 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...